HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neunteufl, T. Articles by Stefenelli, T. Search for Related Content PubMed PubMed Citation Articles by Neunteufl, T. Articles by Stefenelli, T.

CLINICAL STUDY: ENDOTHELIAL FUNCTION

Contribution of nicotine to acute endothelial dysfunction in long-term smokers

Thomas Neunteufl, MD^*,*, Sandra Heher, MD^*, Karam Kostner, MD^*, Goran Mitulovic, PhD, Stephan Lehr, Gholamali Khoschsorur, PhD, Rainer W. Schmid, PhD, Gerald Maurer, MD, FACC^* and Thomas Stefenelli, MD, FACC^*

^* Department of Cardiology, University of Vienna, Vienna, Austria
Clinical Chemistry, University of Vienna, Vienna, Austria
Institute for Medical Statistics, University of Vienna, Vienna, Austria
Institute of Biochemistry, University of Graz, Graz, Austria

Manuscript received July 19, 2000; revised manuscript received July 24, 2001, accepted October 17, 2001.

^* Reprint requests and correspondence: Dr. Thomas Neunteufl, Department of Cardiology, University of Vienna Medical School, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
thomas.neunteufl{at}univie.ac.at

	Abstract

Top Abstract Methods Results Discussion References

 
OBJECTIVES: The aim of this study was to determine whether nicotine, a constituent of cigarette smoke, contributes to acute endothelial dysfunction after smoking one cigarette.

BACKGROUND: Animal studies suggest that nicotine might cause an impairment of endothelium-dependent vasodilation via an increase in oxidative stress.

METHODS: Sixteen healthy smokers were entered into a randomized, observer-blinded crossover study comparing the effects of nicotine nasal spray (1-mg nicotine) and cigarette smoke (1-mg nicotine, 12 mg tar) on vascular reactivity in the brachial artery. Using high-resolution ultrasound, flow-mediated dilation (FMD) and endothelium-independent, nitroglycerin-induced dilation were assessed at baseline and 20 min after the administration of nicotine (spray or cigarette).

RESULTS: In response to similar increases in nicotine serum levels, FMD values declined from 10.2 ± 4.4% to 6.7 ± 4.0% after the spray (mean difference: –3.6 ± 2.0%, 95% confidence interval: –4.6; –2.5, p < 0.0001) and from 9.4 ± 3.8% to 4.3 ± 2.8% after the cigarette (–5.1 ± 2.6%, –6.5; –3.7, p < 0.0001). Nitroglycerin-induced dilation remained similar within both periods. Performing a period effect analysis of variance, a significant influence on FMD was found for the mode of administration (p = 0.017) and the baseline value (p = 0.021). The effect on FMD was more pronounced after the cigarette than after the spray (estimated average effect difference: 1.9% FMD). Oxidation parameters did not increase significantly after nicotine spray or tobacco exposure.

CONCLUSIONS: These results demonstrate that nicotine alone causes acute endothelial dysfunction, although to a lesser extent than smoking a cigarette of the same nicotine yield. However, the precise mechanisms by which nicotine leads to this altered vascular reactivity remain unclear.

Endothelial dysfunction, an early marker of atherosclerosis, has been observed in chronic smokers as well as after acute cigarette smoking (8–10). However, the precise mechanisms causing this altered vascular reactivity are not fully understood and may be complex. Furthermore, the mechanisms causing acute endothelial dysfunction may be different from those leading to chronic endothelial dysfunction (11). Animal studies examining the effects of nicotine on endothelial function produced controversial results. Chronic nicotine exposure did not effect peripheral vascular reactivity in the rat, neither at low nor at high concentrations (12). In contrast, endothelium-dependent dilation of arterioles in the hamster was modestly impaired by infusion of low concentrations of nicotine and markedly by high concentrations causing an increase in nicotine plasma levels (13). Moreover, an impairment of endothelium-dependent arteriolar dilation has been observed in the hamster after chronic exposure to nicotine and after acute infusion of nicotine (14,15). Reversibility of these effects by superperfusion with superoxide dismutase suggested a causal role of oxidative stress (15). The concept that nicotine causes endothelial dysfunction via an increase in oxidative stress has been recently supported by a study demonstrating that exposure of endothelial cells to nicotine in vitro and in vivo increases superoxide anion production and endothelial adhesiveness for monocytes (16).

It is further conceivable that cigarette smoke contains other substances such as carbon monoxide, inducing significant effects on vascular reactivity (17). Recently, it has been shown that acute local exposure to nicotine impairs endothelium-dependent vasodilation in human veins in vivo (18).

The aim of this study was to determine whether nicotine alone causes acute endothelial dysfunction in the brachial artery of long-term smokers and whether nicotine replacement therapy is less harmful for the integrity of endothelial function than smoking a cigarette containing the same amount of nicotine.

	Methods

Top Abstract Methods Results Discussion References

 
Study design.   This is an observer-blinded, randomized crossover study examining the effects of nicotine nasal spray and cigarette smoke on vascular reactivity in random order. Subjects received two sprays of a nicotine nasal spray (Nicotrol NS, Pharmacia and Upjohn, Vienna, Austria) or smoked one cigarette (Camel Filters, R. J. Reynolds Tobacco Co., Winston-Salem, North Carolina). Each 10-ml spray bottle contains 100-mg nicotine (10 mg/ml) in an inactive vehicle. After priming the delivery system for Nicotrol NS, each actuation of the unit delivers a metered dose spray containing approximately 0.5 mg of nicotine. The smoking machine determined the nicotine yield for one cigarette as 1-mg nicotine. An additional randomized, observer-blinded crossover study compared the effects of nicotine nasal spray and nicotine nasal spray placebo on flow-mediated dilation (FMD) in the brachial artery.

Studies were always conducted at the same time of day (between 3 PM and 5 PM) after fasting for 6 h. Subjects stopped smoking 2 h before the study and did not change smoking habits from day 1 to day 2. Blood samples were drawn 5 min before and 10 min after the administration of nicotine nasal spray or the ending of smoking a cigarette. Flow-mediated dilation and nitroglycerin-induced dilation (NMD) were evaluated at baseline and 20 min after the administration of a nicotine nasal spray or ending of smoking a cigarette on two subsequent days.

Study population.   Sixteen young healthy smokers were enrolled into the study. No participant had a history of hypercholesterolemia, hypertension or diabetes mellitus. None of the participants took antioxidative drugs before or during this study. The investigations conformed to the principles outlined in the Declaration of Helsinki, and the local human subjects committee approved the study protocol. Written, informed consent was obtained from all participants.

Assessment of FMD and blood flow.   Endothelium-dependent FMD after reactive hyperemia and endothelium-independent NMD were examined in the brachial artery according to the method described by Celermajer et al. (19). Using high-resolution ultrasound (7.5-MHz linear array transducer), measurements of the right brachial artery were taken at rest after lying quietly for at least 10 min after cuff deflation, after completing suprasystolic compression (250 mm Hg for 4.5 min) of the right upper arm and after sublingual application of 0.8-mg nitroglycerin. Scans of the brachial artery were taken proximal to the bifurcation of the radial and the ulnar artery by the same ultrasound operator. Diameter measurements were taken from one media-adventitia interface to the other for at least three times at baseline and every 20 s after reactive hyperemia and after administration of nitroglycerin. The maximum FMD and NMD diameters were calculated as the average of the three consecutive maximum diameter measurements after hyperemia and nitroglycerin, respectively. The FMD and NMD were then calculated as the percent change in diameter compared with baseline. The impairment of FMD after the application of nicotine (deltaFMD) was estimated as the percent change in FMD values compared with baseline. To verify that suprasystolic compression of the brachial artery caused adequate increases in blood flow, flow velocity was measured at rest and within 15 s after cuff deflation. Blood flow was calculated by multiplying the velocity time integral by the heart rate and the vessel cross-sectional area (3.14 x D²/4). Reactive hyperemia was then calculated as percent change in flow during hyperemia compared with baseline.

Determination of nicotine in serum by high-pressure liquid chromatography (HPLC)/mass spectrometry.   (S)-(–)-nicotine 98% was purchased from Aldrich (Vienna, Austria); nicotine-methyl-d3 as internal standard was obtained from Cambridge Isotope Laboratories, Inc. (Andover, Massachusetts). Acetonitrile LiChrosolv, ammonium acetate p. a. and n-butyl acetate HPLC grade was purchased from Merck (Darmstadt, Germany), and methanol Chromasolv was obtained from Riedel de Haen (Selze, Germany).

The HPLC system consisted of Jasco Pu 980 pump, Jasco LG-98002 Ternary Gradient Unit, CMA/260 degasser and a Merck-Hitachi As-4000 intelligent auto sampler equipped with 20-µl sample loop and six-port valve.

The mass spectrometer used was a VG Quattro (Micromass, Altrinchham, United Kingdom) operating in positive ApcI (atmospheric pressure chemical ionization) mode and using electrospray inlet. The corona discharge needle voltage was set to 3.5 kV; source temperature was 100°C, and mobile phase was acetonitrile/methanol/10 mM ammonium acetate (53/32/15, v/v/v), pHa-7.8. The chromatographic column used for the separation was Merck Purospher Star RP-18 endcapped, 30 x 2 mm, and the chromatographic separation was performed at ambient temperature.

A sample preparation consisted of 500 µl serum spiked with 100 µl of internal standard (400 pg/µl) prepared in methanol and extracted with 1 ml of n-butyl acetate for 10 min. The mixture was centrifuged for 5 min, and the organic phase was transferred into the clean 1.5-ml Eppendorf vial. The organic solvent was evaporated in Speedvac concentrator at ambient temperature to near dryness. The residue was dissolved in 100 µl of mobile phase, and 20 µl of it was injected into the chromatographic system.

The increase of nicotine (delta nicotine) after the application of nicotine was calculated as the percent change in nicotine compared with baseline.

Determination of oxidation parameters.   The measurements of thiobarbituric acid reactive substances (TBARS) are based on the reaction of malondialdehyde (MDA), a secondary breakdown product of lipid hydroperoxides (LPO), with thiobarbituric acid. The assay was performed as described previously (20). Lipid hydroperoxides were determined by a method described by Tateishi et al. (21) using a commercial kit from Kamya company (Seattle, Washington). Peroxidation of polyunsaturated fatty acids leads to the formation of a conjugated diene (DIENE) system, with a characteristic ultraviolet absorption maximum at 234 nm. The measurement of DIENE was performed as described previously (22). Plasma malondialdehyde concentrations were measured after derivatization by thiobarbituric acid and separation on HPLC (MDA-HPLC), as reported previously (23,24).

Statistical analyses.   Results are expressed as mean ± SD. Paired t tests (baseline vs. post-treatment values) were performed to examine whether the administration of nicotine has an effect on FMD. The 95% confidence interval (CI) for the mean difference (post – baseline values) was calculated for both periods. Analysis of variance (ANOVA) with the factors mode of administration (2 levels: cigarette, coded with 1 and spray coded with 0), day of administration (2 levels: first and second day), sequence (2 levels: spray/cigarette and cigarette/spray), gender and the interaction between sequence and gender, the random factor patient within sequence and gender (16 levels) and the covariable baseline FMD value was performed for the post-, pre- difference to examine the different effect of the nicotine nasal spray and the cigarette smoke on FMD. The same ANOVA model was used to examine the different effects of nicotine nasal spray and nicotine nasal spray placebo on FMD. The ANOVA model was calculated using proc glm with the test option within the SAS computer package (Release 6.12, SAS Institute, Cary, North Carolina). Paired t test was performed to examine whether nicotine serum levels differed between the spray period and the cigarette period. Correlation analysis was performed to examine the association of changes in nicotine serum levels with the impairment of FMD. Analysis of variance with the results were considered significant at p <0.05.

	Results

Top Abstract Methods Results Discussion References

 
Clinical and biochemical parameters.   Sixteen chronic smokers (13.4 ± 6.5 cigarettes per day, 4.3 ± 2.4 pack years), eight men and eight women, were enrolled into this study. Subjects were characterized as follows: age: mean ± SD: 24.9 ± 1.9 years, body mass index: 21.5 ± 2.6, total serum cholesterol: 4.69 ± 0.98 mmol/l, low-density lipoprotein cholesterol: 2.55 ± 0.80 mmol/l, high-density lipoprotein cholesterol: 1.52 ± 0.44 mmol/l, triglycerides: 1.35 ± 0.76 mmol/l. Levels of nicotine were similar in both study groups at baseline (spray vs. cigarette: 13.78 ± 8.09 ng/ml vs. 13.25 ± 4.57 ng/ml, p = 0.805) and after application of nicotine (spray vs. cigarette: 19.91 ± 16.63 ng/ml vs. 18.98 ± 6.93 ng/ml, p = 0.764). Both nasal spray and cigarette smoke resulted in significant increases of nicotine serum levels (spray: p = 0.027; cigarette: p = 0.003). With regard to TBARS, DIENE, LPO and MDA-HPLC, no significant increases were observed either after nicotine nasal spray or after cigarette smoking.

FMD and blood flow responses.   Flow-mediated dilation values declined from 10.2 ± 4.4% to 6.7 ± 4.0% after the spray (mean post/baseline difference: –3.6 ± 2.0%, 95% CI: –4.6; –2.5, p < 0.0001) and from 9.4 ± 3.8% to 4.3 ± 2.8% after the cigarette (mean post/baseline difference: –5.1 ± 2.6%, 95% CI: –6.5; –3.7, p < 0.0001) (Fig. 1). The changes in FMD were influenced by the mode of administration and the baseline value but not by the day of administration, the sequence, the gender or the sequence x gender interaction. On both days the mean FMD difference was less pronounced after the spray than after the cigarette (first day: –4.0 ± 1.7% vs. –5.2 ± 2.8%, second day: –3.1 ± 2.2% vs. –5.3 ± 2.8%). The estimated average effect difference was 1.9% FMD. Vessel size (baseline vs. after spray: 3.4 ± 0.7 mm vs. 3.4 ± 0.6 mm, p = 0.096; baseline vs. after cigarette: 3.4 ± 0.6 mm vs. 3.4 ± 0.5 mm, p = 0.669) and NMD (baseline vs. after spray: 15.3 ± 5.0% vs. 14.0 ± 5.5%, p = 0.124; baseline vs. after cigarette: 14.3 ± 4.5% vs. 13.8 ± 5.2%, p = 0.517) remained similar after the administration of 1-mg nicotine and were not affected by the mode of administration. Increases in blood flow during reactive hyperemia increased slightly but not significantly after the spray (430 ± 267% vs. 551 ± 384%, p = 0.058) and after the cigarette (402 ± 239% vs. 551 ± 384%, p = 0.216). The impairment of FMD was not related to increases of nicotine serum levels after cigarette smoking and nicotine nasal spray, respectively.

View larger version (17K): [in this window] [in a new window]   Figure 1 Flow-mediated dilation (FMD) values before and after the administration of nicotine nasal spray (1-mg nicotine) and smoking a cigarette (1-mg nicotine, 12-mg tar), respectively.

	Discussion

Top Abstract Methods Results Discussion References

 
Our findings show that the administration of two sprays of nicotine nasal spray containing 1 mg of nicotine causes endothelial dysfunction in the brachial artery of chronic smokers, although to a lesser extent than smoking a cigarette with a machine-determined nicotine yield of 1-mg nicotine, suggesting that nicotine contributes to acute endothelial dysfunction after cigarette smoking.

Cigarette smoking and cardiovascular disease.   Chronic smokers are at increased risk of acute MI, unstable angina and sudden death (25). Moreover, cigarette smoking causes immediate constriction of epicardial coronary arteries and an increase in coronary artery resistance vessel tone despite an increase in myocardial oxygen demand (26), and the stimulation of coronary artery alpha-adrenergic receptors by circulating or locally released catecholamines may be responsible for these effects (27). On the other hand, the integrity of vascular endothelial cell function may play a key role in determining the vascular response to cigarette smoking (28,29). The mechanisms by which cigarette smoking leads to endothelial dysfunction are gradually being revealed. Oxidative stress may mediate this adverse effect since cigarette smoke contains large amounts of free radicals such as superoxide anion and hydroxyl radicals (30,31) that degrade nitric oxide (NO) released from the endothelium. Indeed, antioxidants such as vitamin E and C have been shown to attenuate the impairment of endothelium-dependent vasodilation after heavy cigarette smoking, due to an improvement of the antioxidant status (11,30). Recently, tetrahydrobiopterin supplementation has been shown to improve FMD in long-term smokers, supporting the concept that, in addition to the free radical burden of cigarette smoke, a dysfunctional NO synthase due to tetrahydrobiopterin depletion may contribute, at least in part, to endothelial dysfunction in smokers (32). Furthermore, inhaling a single cigarette decreased exhaled NO in current smokers, suggesting that it may inhibit the enzyme NO synthase whereas inhalation of NO itself and carbon monoxide, both constituents of tobacco smoke, had no effect on exhaled NO in nonsmoking controls (33).

Nicotine and endothelial function.   The concept that nicotine causes endothelial dysfunction via an increase in oxidative stress has been recently supported by animal studies demonstrating that chronic exposure to nicotine and acute infusion of nicotine cause an impairment of endothelium-dependent arteriolar dilation that can be restored by superperfusion with superoxide dismutase (15). Superoxide causes a loss of the vasodilatory action of NO and yields peroxynitrite at the same time. Subsequently, peroxinitrite causes endothelial cell damage via membrane lipid peroxidation (34) but also nitrates and inactivates PGI2 synthase, leaving unmetabolized prostaglandin H2, which causes vasospasm via the TxA2/prostaglandin H2 receptor (35). Indeed, nicotine has been shown to decrease PGI2 synthesis in the vascular endothelium, whereas it has no effect on thromboxane A2 production (36). However, the contribution of PGI2 to endothelium-dependent relaxation may be less important than its platelet inhibitory effects. Indeed, at least in the porcine coronary circulation, PGI2 contributes very little to the regulation of vascular tone (37). This study extends these findings by demonstrating that nicotine causes endothelial dysfunction in humans. In addition to nicotine, other constituents of cigarette smoke may contribute to acute endothelial dysfunction after cigarette smoking, since nicotine nasal spray caused less impairment of FMD than smoking a cigarette containing the same amount of nicotine. However, the estimated average intake of nicotine is 0.55 mg per nicotine nasal spray (1-mg nicotine) and 1.43 mg per cigarette (1-mg nicotine) (38).

Study limitations.   A possible drawback of this study may be that the nicotine plasma kinetic after the cigarette differs from the kinetic after the spray and that this difference may be responsible for different effects on FMD. Indeed, Gourlay et al. (39) showed that both venous and arterial levels of nicotine after cigarette smoking are much higher and occur much quicker compared with nicotine nasal spray, although the nasal administration system has been developed to more closely approximate cigarette delivery for improved efficacy in clinical application and for more control in systemic testing of nicotine (40). However, in this study, using a protocol different from the one of Gourlay et al. (39), increases of venous nicotine serum levels were not significantly different between the study groups, and nicotine serum levels before the ultrasound examination were very similar in the spray period and in the cigarette period. Thus, mechanisms different from pharmacokinetic factors may have at least contributed to the more adverse effect of cigarette smoking on FMD compared with the nicotine nasal spray. Moreover, this study could not establish oxidative stress as a relevant mechanism for nicotine-induced endothelial dysfunction. Indeed, we cannot exclude that the number of patients enrolled in this study may have been insufficient to show significant increases in oxidation parameters. Thus, further studies enrolling a larger number of patients are required to determine whether nicotine causes endothelial dysfunction, at least in part, via an increase in oxidative stress. However, this study was not designed to examine the long-term effects of nicotine on endothelial function, and the results cannot necessarily be extrapolated to slow-release application of nicotine.

Summary and conclusions.   The findings of this study demonstrate that nicotine causes acute endothelial dysfunction in long-term smokers and suggest that there may be other constituents of cigarette smoke that contribute to this adverse effect. However, the precise mechanisms responsible for this negative effect of nicotine on endothelial function remain unclear. We conclude that nicotine replacement therapy by nasal spray is less harmful for the endothelium than cigarette smoking but fails to preserve the integrity of endothelial function.

	Footnotes

 
Nicotine nasal spray and nicotine nasal spray placebo were provided for free by Pharmacia and Upjohn (Vienna, Austria).

	References

Top Abstract Methods Results Discussion References

 

1. Lakier JB. Smoking and cardiovascular disease. Am J Med. 1992;93:8S–12S[CrossRef][Medline]
2. Ottervanger JP, Wilson JH, Stricker BH. Drug-induced chest pain and myocardial infarction: reports to a national centre and review of the literature. Eur J Clin Pharmacol. 1997;53:105–110[CrossRef][Medline]
3. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993;22:1159–1167[Abstract]
4. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–1798[Abstract/Free Full Text]
5. Huhtasaari F, Lundberg V, Eliasson M, Janlert U, Asplund K. Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. J Am Coll Cardiol. 1999;34:1784–1790[Abstract/Free Full Text]
6. Huhtasaari F, Asplund K, Lundberg V, Stegmayr B, Wester PO. Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? Br Med J. 1992;305:1252–1256[Medline]
7. Bolinder G, Noren A, de Fair U, Wahren J. Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis. 1997;132:95–103[CrossRef][Medline]
8. Zeiher AM, Schächinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation. 1995;92:1094–1100[Abstract/Free Full Text]
9. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149–2155[Abstract/Free Full Text]
10. Lekakis J, Papamichael C, Vemmos C, et al. Effect of acute cigarette smoking on endothelium-dependent brachial artery dilation in healthy individuals. Am J Cardiol. 1997;79:529–531[CrossRef][Medline]
11. Neunteufl T, Priglinger U, Heher S, et al. Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. J Am Coll Cardiol. 2000;35:277–283[Abstract/Free Full Text]
12. Li Z, Barrios V, Buchholz JN, Glenn TC, Duckles SP. Chronic nicotine administration does not affect peripheral vascular reactivity in the rat. J Pharmacol Exp Ther. 1994;271:1135–1142[Abstract/Free Full Text]
13. Mayhan WG, Patel KP. Effect of nicotine on endothelium-dependent arteriolar dilatation in vivo. Am J Physiol. 1997;272:H2337–2342
14. Mayhan WG, Sharpe GM. Chronic exposure to nicotine alters endothelium-dependent arteriolar dilatation: effect of superoxide dismutase. J Appl Physiol. 1999;86:1126–1134[Abstract/Free Full Text]
15. Mayhan WG, Sharpe GM. Superoxide dismutase restores endothelium-dependent arteriolar dilatation during acute infusion of nicotine. J Appl Physiol. 1998;85:1292–1298[Abstract/Free Full Text]
16. Tsao PS, Cooke JP. Nicotine induces endothelial oxidative stress and monocyte adherence. (abstr)Circulation. 1999;100:I693
17. Kozma F, Johnson RA, Zhang F, et al. Contribution of endogenous carbon monoxide to regulation of diameter in resistance vessels. Am J Physiol. 1999;274:R1087–1094
18. Chalon S, Moreno H, Benowitz NL, Hoffmann BB, Blaschke TF. Nicotine impairs endothelium-dependent dilation in human veins in vivo. Clin Pharmacol Ther. 2000;67:391–397[CrossRef][Medline]
19. Celermajer DS, Sorensen KE, Gooch VM, et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–1115[CrossRef][Medline]
20. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Meth Enzymol. 1990;186:407[Medline]
21. Tateishi T, Yoshimine N, Kuzuya F. Serum lipid peroxide measured by a new colorimetric method. Exp Ger. 1987;22:103–105
22. Chajes V, Sattler W, Stultschnig M, Kostner G. Photometric evaluation of lipid peroxidation products in human plasma and copper oxidized low density lipoproteins: correlation of different oxidation parameters. Atherosclerosis. 1996;121:193–203[CrossRef][Medline]
23. Wong SHY, Knight JA, Hopfer SM, Zaharia O, Leach CN Jr, Sunderman FW Jr. Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin Chem. 1987;33:214–220[Abstract/Free Full Text]
24. Winkelhofer-Roob BM, Puhl H, Khoschsorur G, van’t Hof MA, Esterbauer H, Shmerling DH. Enhanced resistance to oxidation of low density lipoprotein and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis. Free Radical Biol Med. 1995;18:849–859[CrossRef][Medline]
25. Zhu B, Parmley WW. Hemodynamic and vascular effects of active and passive smoking. Am Heart J. 1995;130:1270–1275[CrossRef][Medline]
26. Quillen JE, Rossen JD, Oskarsson HJ, Minor RL Jr, Lopez AG, Winniford MD. Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. J Am Coll Cardiol. 1993;22:642–647[Abstract]
27. Winniford MD, Wheelan KR, Kremers MS, et al. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone. Circulation. 1986;73:662–667[Abstract/Free Full Text]
28. Vita JA, Treasure CB, Yeung AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation. 1992;85:1390–1397[Abstract/Free Full Text]
29. Zeiher AM, Drexler H, Wollschlaeger H, Saurbier B, Just H. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol. 1989;14:1181–1190[Abstract]
30. Heitzer T, Just H, Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 1996;94:6–9[Abstract/Free Full Text]
31. Motoyama T, Kawano H, Kugiyama K, et al. Endothelium-dependent vasodilation in the brachial artery is impaired in smokers: effect of vitamin C. Am J Physiol. 1997;273:H1644–1650
32. Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol. 2000;35:71–75[Abstract/Free Full Text]
33. Kharitonov SA, Robbins RA, Yates D, et al. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med. 1995;152:609–612[Abstract]
34. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991;288:481–487[CrossRef][Medline]
35. Zou MH, Bachschmid M. Hypoxia-reoxygenation triggers coronary vasospasm in isolated bovine coronary arteries via tyrosine nitration of prostacyclin synthase. J Exp Med. 1999;190:135–139[Abstract/Free Full Text]
36. Klein LW. Cigarette smoking, atherosclerosis and the coronary hemodynamic response: a unifying hypothesis. J Am Coll Cardiol. 1984;4:972–974[Medline]
37. Richard V, Tanner FC, Tschudi M, Lüscher TF. Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries. Am J Physiol. 1990;259:H1433–1439
38. Benowitz NL, Zevin S, Jacob P III. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray transdermal nicotine and cigarette smoking. Br J Clin Pharmacol. 1997;43:259–267[CrossRef][Medline]
39. Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther. 1997;62:453–463[CrossRef][Medline]
40. Schneider NG, Lunell E, Olmstead RE, Fagerstrom KO. Clinical pharmacokinetics of nasal nicotine delivery: a review and comparison to other nicotine systems. Clin Pharmacokinet. 1996;31:65–80[Medline]

This article has been cited by other articles:

				H. Gullu, M. Caliskan, O. Ciftci, D. Erdogan, S. Topcu, E. Yildirim, A. Yildirir, and H. Muderrisoglu Light cigarette smoking impairs coronary microvascular functions as severely as smoking regular cigarettes Heart, October 1, 2007; 93(10): 1274 - 1277. [Abstract] [Full Text] [PDF]

				A. Siafaka, E. Angelopoulos, K. Kritikos, M. Poriazi, N. Basios, V. Gerovasili, A. Andreou, C. Roussos, and S. Nanas Acute Effects of Smoking on Skeletal Muscle Microcirculation Monitored by Near-Infrared Spectroscopy Chest, May 1, 2007; 131(5): 1479 - 1485. [Abstract] [Full Text] [PDF]

				K. H. Ginzel, G. S. Maritz, D. F. Marks, M. Neuberger, Jim. R. Pauly, J. R. Polito, R. Schulte-Hermann, and T. A. Slotkin Critical Review: Nicotine for the Fetus, the Infant and the Adolescent? J Health Psychol, March 1, 2007; 12(2): 215 - 224. [Abstract] [PDF]

				K. Morita, T. Tsukamoto, M. Naya, K. Noriyasu, M. Inubushi, T. Shiga, C. Katoh, Y. Kuge, H. Tsutsui, and N. Tamaki Smoking Cessation Normalizes Coronary Endothelial Vasomotor Response Assessed with 15O-Water and PET in Healthy Young Smokers J. Nucl. Med., December 1, 2006; 47(12): 1914 - 1920. [Abstract] [Full Text] [PDF]

				P. C. Strike and A. Steptoe Behavioral and Emotional Triggers of Acute Coronary Syndromes: A Systematic Review and Critique Psychosom Med, March 1, 2005; 67(2): 179 - 186. [Abstract] [Full Text] [PDF]

				F. Wiesmann, S. E. Petersen, P. M. Leeson, J. M. Francis, M. D. Robson, Q. Wang, R. Choudhury, K. M. Channon, and S. Neubauer Global impairment of brachial, carotid, and aortic vascular function in young smokers: Direct quantification by high-resolution magnetic resonance imaging J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2056 - 2064. [Abstract] [Full Text] [PDF]

				A. Soghomonians, T. L. Thirkill, N. F. Mariano, A. I. Barakat, and G. C. Douglas Effect of Aqueous Tobacco Smoke Extract and Shear Stress on PECAM-1 Expression and Cell Motility in Human Uterine Endothelial Cells Toxicol. Sci., October 1, 2004; 81(2): 408 - 418. [Abstract] [Full Text] [PDF]

				A. Vychytil, M. Fodinger, J. Pleiner, M. Mullner, P. Konner, S. Skoupy, C. Rohrer, M. Wolzt, and G. Sunder-Plassmann Acute effect of amino acid peritoneal dialysis solution on vascular function Am. J. Clinical Nutrition, November 1, 2003; 78(5): 1039 - 1045. [Abstract] [Full Text] [PDF]

				M. Kimura, Y. Higashi, K. Hara, K. Noma, S. Sasaki, K. Nakagawa, C. Goto, T. Oshima, M. Yoshizumi, and K. Chayama PDE5 Inhibitor Sildenafil Citrate Augments Endothelium-Dependent Vasodilation in Smokers Hypertension, May 1, 2003; 41(5): 1106 - 1110. [Abstract] [Full Text] [PDF]

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neunteufl, T. Articles by Stefenelli, T. Search for Related Content PubMed PubMed Citation Articles by Neunteufl, T. Articles by Stefenelli, T.